Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6265536 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Sep, 2015
(8 years ago) | |
US6107458 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Mar, 2019
(5 years ago) | |
US6774104 | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jan, 2021
(3 years ago) | |
US6774104 (Pediatric) | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jul, 2021
(2 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Jun 20, 2023 |
New Indication(I-821) | Dec 20, 2022 |
Market Authorisation Date: 16 March, 2005
Treatment: Treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients; Treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses
Dosage: INJECTABLE;INTRAVENOUS